This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy

InOncology.com

Article library

 

This section contains a detailed bibliography of clinical data for afatinib* and nintedanib**, including trials, subgroup analyses, real-world data, case studies and review articles. Please use the filters to find publications in your area of interest. Alternatively, please select the compound of interest to group articles together and introduce further filter options for tumour entity, setting and patient population.

*Afatinib is approved in more than 70 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information.

**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.

Filter by:

Showing 1-10 of 281 Articles

Title Citation Focus area Phase

PIVOTAL TRIAL DATA FOR LUX-LUNG 3

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations

Sequist LV, et al. J Clin Oncol 2013;31(27):3327-3334
  1. 1
  2. 2
  3. 3
  4. A

LUME LUNG 1 PIVOTAL DATA TRIAL

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

Reck M, et al. Lancet Oncol 2014;15(2):143-155 Non-small cell lung cancer first line epidermal growth factor mutation-positive
  1. 1
  2. 2
  3. 3
  4. A